Drug Profile
DSP 2230
Alternative Names: ANP-230; DSP-2230Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer AlphaNavi Pharma; Sumitomo Pharma
- Class Analgesics
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors; Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Pain
- No development reported Neuropathic pain
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 28 Apr 2021 No recent reports of development identified for phase-I development in Neuropathic-pain in Japan (PO, Suspension)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Neuropathic-pain in USA (PO, Suspension)